NPS Pharmaceuticals (NPSP) PT Raised at FBR Capital on Expected FDA Approval Following Briefing Docs
Tweet Send to a Friend
FBR Capital raised its price target on Outperform-rated NPS Pharmaceuticals Inc. (NASDAQ: NPSP to $36.00 (from $34.00) following their assessment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
